FDA mandates enhanced safety check on TNF blockers
FDA is requiring that manufacturers of tumor necrosis factor blockers perform enhanced safety surveillance, the agency said on November 3 in an ongoing safety review of this class of biologic products.
FDA is requiring that manufacturers of tumor necrosis factor (TNF) blockers perform enhanced safety surveillance in children, teenagers, and young adults, the agency said on November 3 in an ongoing safety review of this class of biologic products.
Manufacturers are expected to conduct thorough follow-up of reports of malignancy cases involving TNF blockers and submit all reports of malignancy to FDA as expedited reports (within 15 days) for pediatric and young adult patients (aged 30 years or younger). Manufacturers also will provide annual summaries and assessments of malignancies and TNF blocker utilization data to FDA.
This type of safety surveillance is important for the improved understanding of malignancies in pediatric and young adult patients treated with TNF blockers. It will allow FDA to capture and analyze all reported malignancies based on more complete, consistent reports, the agency said.
Healthcare workers should remain vigilant for cases of malignancy in patients treated with TNF blockers and report them to the FDA MedWatch program or manufacturer.
FDA will re-evaluate the enhanced surveillance requirement periodically during the next 10 years.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
